Cianchi Fabio, Messerini Luca, Comin Camilla Eva, Boddi Vieri, Perna Federico, Perigli Giuliano, Cortesini Camillo
Department of General Surgery, University of Florence, Florence, Italy.
Dis Colon Rectum. 2007 Sep;50(9):1332-41. doi: 10.1007/s10350-007-0222-9.
There is an increasing need for accurate prognostic stratification of patients with Stage II colorectal cancer to identify a subgroup of high-risk patients who may benefit from adjuvant therapies. This study was designed to evaluate the prognostic impact of a wide spectrum of pathologic parameters in a consecutive series of homogenously treated and well-characterized patients with Stage IIA (T3N0M0) colorectal cancer.
The study included 238 patients operated on by a single surgeon for Stage IIA colorectal tumors. The median postoperative follow-up was 110 (range, 96-120) months. At least 12 lymph nodes were harvested and examined in all the resection specimens. The prognostic value of 13 pathologic parameters, including lymph node occult disease (micrometastases) detected by immunohistochemistry, was investigated.
Multivariate analysis identified tumor growth pattern (expanding or infiltrating; P = 0.01) and extent of tumor spread beyond muscularis propria (< or =5 mm or >5 mm; P = 0.04) as the only factors having independent prognostic value. The combination of these two easily determined parameters allowed us to identify two groups of patients at low risk or high risk of tumor recurrence. The eight-year survival rates were 83.3 and 53.4 percent for the two groups, respectively. The high-risk group comprised those patients with infiltrating tumors and extramural tumor spread > 5 mm.
We propose a new and simple prognostic model to identify patients with high-risk Stage IIA colorectal cancer for whom adjuvant therapies may be justified and effective.
对II期结直肠癌患者进行准确的预后分层以识别可能从辅助治疗中获益的高危患者亚组的需求日益增加。本研究旨在评估一系列病理参数对连续系列接受同质化治疗且特征明确的IIA期(T3N0M0)结直肠癌患者的预后影响。
该研究纳入了由一名外科医生对IIA期结直肠肿瘤进行手术的238例患者。术后中位随访时间为110(范围96 - 120)个月。所有切除标本均至少采集并检查12枚淋巴结。研究了13项病理参数的预后价值,包括通过免疫组化检测的淋巴结隐匿性疾病(微转移)。
多因素分析确定肿瘤生长模式(膨胀性或浸润性;P = 0.01)和肿瘤超出固有肌层的扩散范围(≤5 mm或>5 mm;P = 0.04)是仅有的具有独立预后价值的因素。这两个易于确定的参数相结合使我们能够识别出两组肿瘤复发低风险或高风险的患者。两组的八年生存率分别为83.3%和53.4%。高危组包括那些肿瘤为浸润性且壁外肿瘤扩散>5 mm的患者。
我们提出了一种新的、简单的预后模型,以识别IIA期高危结直肠癌患者,对其进行辅助治疗可能是合理且有效的。